Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DS-8895a in Advanced EphA2 Positive Cancers
NCT02252211Phase 1Completed
- Sponsor
- Ludwig Cancer Research
- Start
- Dec 2014
- Primary completion
- Sep 2016
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of DS-8895a in solid tumor, sponsored by Ludwig Cancer Research. Primary endpoint: Number of Patients With Treatment-emergent Adverse Events up to 58 weeks. Started Dec 2014; status: completed.
02
Drugs
DS-8895a
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02252211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02252211.